TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
←

david

T1 · high-signal investor

Co-host of the Acquired podcast with Ben. Former venture capitalist. Leads the storytelling and historical research for episodes. Interviewed Andrew Ross Sorkin about his career across journalism, TV, and events.

1 call·1 name·100% bull·last heard 3 months ago·SeedRocket TV
track record

no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY

top calls

highest conviction · one per company
1sthigh conviction
$SPCXSpaceX

David analyzes SpaceX at $1.75T valuation: Starlink cash flow, vertical integration, and Mars optionality

SpaceX dominates launch with 60% market share and 90% cost reduction via vertical integration and reusability; Starlink provides $11.4B recurring revenue at 50% margins funding Starship development; NASA contracts de-risk capital intensity; orbital data centers and Mars colonization provide optionality justifying 94x revenue multiple.

SeedRocket TV2026-07episode →

most discussed · click a bar to filter

  • $SPCX

recurring themes

  • Robotics & Physical AI2
  • Medical Imaging & Diagnostics1
  • AI in Healthcare1
1 total
$SPCX
···
SpaceX
HIGHdavid·SeedRocket TV·3 months ago·INFLUENCERS jugando a INVERSORES, SpaceX a 2 BILLONES y 3 MILLONES EN LLAMAS entre Socios -Tertulia
David analyzes SpaceX at $1.75T valuation: Starlink cash flow, vertical integration, and Mars optionality
SpaceX dominates launch with 60% market share and 90% cost reduction via vertical integration and reusability; Starlink provides $11.4B recurring revenue at 50% margins funding Starship development; NASA contracts de-risk capital intensity; orbital data centers and Mars colonization provide optionality justifying 94x revenue multiple.
"Bueno, el tema no es tanto eh que es lo impresionante de esta compañía, ¿no? Sino e ni por qué ha salido por 1.75, sino por qué precisamente SpaceX, eh, y no Blue Origin, que es m…"
48:48
9
Robotics & Physical AItailwind
AI moves from digital to physical: robots need nervous systems, not just brains
Multiple founders (Neura, Allen Control, Prometheus, Baseten) converge on thesis that physical AI requires reflexes/nervous system trained in distributed real-world 'neural gyms'; manufacturing, defense, and logistics are first verticals; European auto supply chains being converted for robotics-grade sensors.
8
Medical Imaging & Diagnosticstailwind
Synthetic DNA spike-in converts liquid biopsy noise into solvable math problem
BillionToOne's core innovation—adding known synthetic DNA before PCR amplification to quantify and subtract noise—transforms the needle-in-haystack detection of rare cell-free DNA (fetal or tumor) into a mathematical correction problem, enabling non-invasive prenatal testing and minimal residual disease detection with unprecedented sensitivity.
8
Robotics & Physical AItailwind
Humanoid robots (Optimus) to build Mars bases; Bank of America sees 10M units by 2035
Tesla's Optimus humanoids (22 DOF hands) will precede humans to Mars for base construction; Chinese humanoid videos show rapid progress; Bank of America estimates 1.2M humanoids by 2030 and 10M by 2035, potentially justifying Tesla $3T valuation and SpaceX Mars economics.
6
AI in Healthcaretailwind
AI-powered computer vision automates sample accessioning to enable 2M tests/year scale
BillionToOne redesigned its lab workflow with AI-driven computer vision to handle sample logging in 60 seconds per sample, eliminating a critical manual bottleneck and enabling a single facility to process up to 2 million tests annually—demonstrating how AI automation unlocks throughput for high-volume molecular diagnostics.